Dapagliflozin as monotherapy showed better glycemic control in adult naïve to treatment with type 2 diabetes results from a phase-24 weeks 3 clinical study published online in the last issue of Diabetes Care demonstrated that dapagliflozin investigational drug, administered as monotherapy, achieved half a statistically significant reduction of 5 mg and 10 mg once daily dose in the primary endpoint of glycosylated hemoglobin (HbA1c) in adult patients naïve newly diagnosed …
UTIs – Symptoms & Prevention – What a Relief!